Back

Matrix metalloproteinases proteolyze RAB proteins and contribute to cisplatin-induced ototoxicity

Bhavsar, A. P.; Zandi, Z.; Hartley, B.; Bassiouni, W.; DuVal, M. G.; Luo, S.; Spavor, M. J.; Allison, W. T.; Julien, O.; Schulz, R.

2026-03-03 pharmacology and toxicology
10.64898/2026.02.28.708770 bioRxiv
Show abstract

Matrix metalloproteinases (MMPs) are rapidly expressed and activated in response to oxidative stress and contribute to various pathological conditions. Cisplatin is a highly effective chemotherapeutic agent; however, its clinical use is limited by its associated permanent hearing loss (ototoxicity). While cispwlatin-induced oxidative stress and inner ear cell death are well-established, the contribution of MMPs remains unclear. In this study, we demonstrate that cisplatin exposure triggers activation of MMP-2 and MMP-9 and expression of an intracellular N-terminal-truncated isoform of MMP-2 in mouse inner ear hair cells. Pharmacological inhibition of MMP-2 and genetic knockdown of Mmp-9 enhanced hair cell survival and attenuated cisplatin-induced inflammation and cytotoxicity. Furthermore, proteomic analysis revealed that proteins involved in intracellular trafficking, including RAB proteins, may serve as potential substrates of intracellular MMP-2 upon cisplatin exposure, pointing to a previously unrecognized mechanism of cisplatin-induced hair cell injury. In vitro analysis confirmed that MMP-2 cleaves RAB9A in response to cisplatin, and in silico analyses predicted MMP-2-preferred cleavage sites on RAB9A. Collectively, our findings identify MMP-2 as a promising therapeutic target for mitigating cisplatin-induced ototoxicity.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Clinical and Translational Medicine
30 papers in training set
Top 0.1%
19.2%
2
Scientific Reports
3102 papers in training set
Top 5%
10.4%
3
Frontiers in Pharmacology
100 papers in training set
Top 0.6%
4.3%
4
Archives of Toxicology
14 papers in training set
Top 0.1%
3.7%
5
Clinical and Translational Science
21 papers in training set
Top 0.2%
3.2%
6
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.2%
2.1%
7
eLife
5422 papers in training set
Top 37%
1.9%
8
Science Translational Medicine
111 papers in training set
Top 2%
1.9%
9
Toxicological Sciences
38 papers in training set
Top 0.3%
1.9%
10
PLOS ONE
4510 papers in training set
Top 50%
1.9%
50% of probability mass above
11
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 4%
1.7%
12
Science Advances
1098 papers in training set
Top 16%
1.7%
13
JCI Insight
241 papers in training set
Top 3%
1.7%
14
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 1%
1.7%
15
ACS Chemical Neuroscience
60 papers in training set
Top 1%
1.7%
16
Aging Cell
144 papers in training set
Top 2%
1.4%
17
Advanced Science
249 papers in training set
Top 14%
1.3%
18
ACS Omega
90 papers in training set
Top 2%
1.3%
19
Pharmaceuticals
33 papers in training set
Top 1%
1.0%
20
Cell Death Discovery
51 papers in training set
Top 0.9%
1.0%
21
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
0.9%
22
BMC Medical Genomics
36 papers in training set
Top 0.9%
0.9%
23
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.6%
0.8%
24
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.8%
0.8%
25
International Journal of Molecular Sciences
453 papers in training set
Top 14%
0.8%
26
Communications Biology
886 papers in training set
Top 20%
0.8%
27
EMBO reports
136 papers in training set
Top 6%
0.8%
28
Biomolecules
95 papers in training set
Top 2%
0.8%
29
British Journal of Pharmacology
34 papers in training set
Top 0.5%
0.8%
30
Molecular Therapy
71 papers in training set
Top 3%
0.8%